Loading...
XTAE
GEFR
Market cap55mUSD
Dec 04, Last price  
81.60ILS
1D
2.77%
1Q
10.27%
IPO
-91.32%
Name

Geffen Residence & Renewal Ltd

Chart & Performance

D1W1MN
XTAE:GEFR chart
P/E
P/S
1,365.04
EPS
Div Yield, %
Shrs. gr., 5y
94.80%
Rev. gr., 5y
%
Revenues
131k
-7.75%
0000017,916,000658,00060,000142,000131,000
Net income
-5m
L-26.58%
-1,516,000-140,000-3,076,000-851,000-9,380,000-8,809,000-13,426,000-20,082,000-6,910,000-5,073,000
CFO
-16m
L-73.29%
-16,230,000-557,000-1,474,0002,000-4,288,000-6,236,000-15,190,000-11,173,000-61,458,000-16,415,000
Dividend
Sep 30, 20156.6337 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Geffen Residence & Renewal Ltd engages in the cultivation, production, storage, marketing, and sale of medical cannabis in Israel. It owns pharmacies, which sell cosmetics, convenience, and toiletries, as well as pharmacy and natural products, such as marketing prescription drugs, over-the-counter drugs, natural products, and vitamins and supplements. The company also offers plasters and bandages; and thermometer and humidifiers. The company was formerly known as Cannomed Medical Cannabis Industries Ltd. The company was incorporated in 1999 and is based in Tel Aviv-Yafo, Israel.
IPO date
Feb 26, 2010
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT